Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...